{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T02:09:59Z","timestamp":1775182199550,"version":"3.50.1"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"7738","license":[{"start":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T00:00:00Z","timestamp":1546992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T00:00:00Z","timestamp":1546992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2019,1,10]]},"DOI":"10.1038\/s41586-018-0830-7","type":"journal-article","created":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T09:01:38Z","timestamp":1546506098000},"page":"186-191","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":516,"title":["De novo design of potent and selective mimics of IL-2 and IL-15"],"prefix":"10.1038","volume":"565","author":[{"given":"Daniel-Adriano","family":"Silva","sequence":"first","affiliation":[]},{"given":"Shawn","family":"Yu","sequence":"additional","affiliation":[]},{"given":"Umut Y.","family":"Ulge","sequence":"additional","affiliation":[]},{"given":"Jamie B.","family":"Spangler","sequence":"additional","affiliation":[]},{"given":"Kevin M.","family":"Jude","sequence":"additional","affiliation":[]},{"given":"Carlos","family":"Lab\u00e3o-Almeida","sequence":"additional","affiliation":[]},{"given":"Lestat R.","family":"Ali","sequence":"additional","affiliation":[]},{"given":"Alfredo","family":"Quijano-Rubio","sequence":"additional","affiliation":[]},{"given":"Mikel","family":"Ruterbusch","sequence":"additional","affiliation":[]},{"given":"Isabel","family":"Leung","sequence":"additional","affiliation":[]},{"given":"Tamara","family":"Biary","sequence":"additional","affiliation":[]},{"given":"Stephanie J.","family":"Crowley","sequence":"additional","affiliation":[]},{"given":"Enrique","family":"Marcos","sequence":"additional","affiliation":[]},{"given":"Carl D.","family":"Walkey","sequence":"additional","affiliation":[]},{"given":"Brian D.","family":"Weitzner","sequence":"additional","affiliation":[]},{"given":"F\u00e1tima","family":"Pardo-Avila","sequence":"additional","affiliation":[]},{"given":"Javier","family":"Castellanos","sequence":"additional","affiliation":[]},{"given":"Lauren","family":"Carter","sequence":"additional","affiliation":[]},{"given":"Lance","family":"Stewart","sequence":"additional","affiliation":[]},{"given":"Stanley R.","family":"Riddell","sequence":"additional","affiliation":[]},{"given":"Marion","family":"Pepper","sequence":"additional","affiliation":[]},{"given":"Gon\u00e7alo J. L.","family":"Bernardes","sequence":"additional","affiliation":[]},{"given":"Michael","family":"Dougan","sequence":"additional","affiliation":[]},{"given":"K. Christopher","family":"Garcia","sequence":"additional","affiliation":[]},{"given":"David","family":"Baker","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,1,9]]},"reference":[{"key":"830_CR1","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.jaci.2010.11.050","volume":"127","author":"M Akdis","year":"2011","unstructured":"Akdis, M. et al. Interleukins, from 1 to 37, and interferon-\u03b3: receptors, functions, and roles in diseases. J. Allergy Clin. Immunol. 127, 701\u2013721 (2011).","journal-title":"J. Allergy Clin. Immunol."},{"key":"830_CR2","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.0105-2896.2004.00199.x","volume":"202","author":"MJ Smyth","year":"2004","unstructured":"Smyth, M. J., Cretney, E., Kershaw, M. H. & Hayakawa, Y. Cytokines in cancer immunity and immunotherapy. Immunol. Rev. 202, 275\u2013293 (2004).","journal-title":"Immunol. Rev."},{"key":"830_CR3","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.4049\/jimmunol.135.4.2865","volume":"135","author":"MT Lotze","year":"1985","unstructured":"Lotze, M. T. et al. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J. Immunol. 135, 2865\u20132875 (1985).","journal-title":"J. Immunol."},{"key":"830_CR4","doi-asserted-by":"publisher","first-page":"e22882","DOI":"10.7554\/eLife.22882","volume":"6","author":"I Moraga","year":"2017","unstructured":"Moraga, I. et al. Synthekines are surrogate cytokine and growth factor agonists that compel signaling through non-natural receptor dimers. eLife 6, e22882 (2017).","journal-title":"eLife"},{"key":"830_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15373","volume":"8","author":"R Vazquez-Lombardi","year":"2017","unstructured":"Vazquez-Lombardi, R. et al. Potent antitumour activity of interleukin-2\u2013Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells. Nat. Commun. 8, 15373 (2017).","journal-title":"Nat. Commun."},{"key":"830_CR6","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1126\/science.aar3246","volume":"359","author":"JT Sockolosky","year":"2018","unstructured":"Sockolosky, J. T. et al. Selective targeting of engineered T cells using orthogonal IL-2 cytokine\u2013receptor complexes. Science 359, 1037\u20131042 (2018).","journal-title":"Science"},{"key":"830_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.coche.2017.12.003","volume":"19","author":"R Kureshi","year":"2018","unstructured":"Kureshi, R., Bahri, M. & Spangler, J. B. Reprogramming immune proteins as therapeutics using molecular engineering. Curr. Opin. Chem. Eng. 19, 27\u201334 (2018).","journal-title":"Curr. Opin. Chem. Eng."},{"key":"830_CR8","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nature10975","volume":"484","author":"AM Levin","year":"2012","unstructured":"Levin, A. M. et al. Exploiting a natural conformational switch to engineer an interleukin-2 \u2018superkine\u2019. Nature 484, 529\u2013533 (2012).","journal-title":"Nature"},{"key":"830_CR9","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/nbt725","volume":"20","author":"CA Sarkar","year":"2002","unstructured":"Sarkar, C. A. et al. Rational cytokine design for increased lifetime and enhanced potency using pH-activated \u2018histidine switching\u2019. Nat. Biotechnol. 20, 908\u2013913 (2002).","journal-title":"Nat. Biotechnol."},{"key":"830_CR10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev-immunol-032713-120211","volume":"33","author":"JB Spangler","year":"2015","unstructured":"Spangler, J. B., Moraga, I., Mendoza, J. L. & Garcia, K. C. Insights into cytokine-receptor interactions from cytokine engineering. Annu. Rev. Immunol. 33, 139\u2013167 (2015).","journal-title":"Annu. Rev. Immunol."},{"key":"830_CR11","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1158\/1078-0432.CCR-15-1631","volume":"22","author":"DH Charych","year":"2016","unstructured":"Charych, D. H. et al. NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models. Clin. Cancer Res. 22, 680\u2013690 (2016).","journal-title":"Clin. Cancer Res."},{"key":"830_CR12","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1158\/2326-6066.CIR-17-0495","volume":"6","author":"M Dougan","year":"2018","unstructured":"Dougan, M. et al. Targeting cytokine therapy to the pancreatic tumor microenvironment using PD-L1-specific VHHs. Cancer Immunol. Res. 6, 389\u2013401 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"830_CR13","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.1073\/pnas.1416159112","volume":"112","author":"A Tzeng","year":"2015","unstructured":"Tzeng, A., Kwan, B. H., Opel, C. F., Navaratna, T. & Dane Wittrup, K. Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution. Proc. Natl Acad. Sci. USA 112, 3320\u20133325 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"830_CR14","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2015.03.004","volume":"27","author":"EF Zhu","year":"2015","unstructured":"Zhu, E. F. et al. Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2. Cancer Cell 27, 489\u2013501 (2015).","journal-title":"Cancer Cell"},{"key":"830_CR15","doi-asserted-by":"publisher","first-page":"4982","DOI":"10.1073\/pnas.95.9.4982","volume":"95","author":"DE Kim","year":"1998","unstructured":"Kim, D. E., Gu, H. & Baker, D. The sequences of small proteins are not extensively optimized for rapid folding by natural selection. Proc. Natl Acad. Sci. USA 95, 4982\u20134986 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"830_CR16","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/prot.10016","volume":"46","author":"DM Taverna","year":"2002","unstructured":"Taverna, D. M. & Goldstein, R. A. Why are proteins marginally stable? Proteins 46, 105\u2013109 (2002).","journal-title":"Proteins"},{"key":"830_CR17","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.molcel.2009.11.022","volume":"36","author":"L Foit","year":"2009","unstructured":"Foit, L. et al. Optimizing protein stability in vivo. Mol. Cell 36, 861\u2013871 (2009).","journal-title":"Mol. Cell"},{"key":"830_CR18","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1359-6446(03)02610-2","volume":"8","author":"SA Marshall","year":"2003","unstructured":"Marshall, S. A., Lazar, G. A., Chirino, A. J. & Desjarlais, J. R. Rational design and engineering of therapeutic proteins. Drug Discov. Today 8, 212\u2013221 (2003).","journal-title":"Drug Discov. Today"},{"key":"830_CR19","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.it.2007.07.011","volume":"28","author":"AS De Groot","year":"2007","unstructured":"De Groot, A. S. & Scott, D. W. Immunogenicity of protein therapeutics. Trends Immunol. 28, 482\u2013490 (2007).","journal-title":"Trends Immunol."},{"key":"830_CR20","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1056\/NEJMoa1516437","volume":"374","author":"F Peyvandi","year":"2016","unstructured":"Peyvandi, F. et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N. Engl. J. Med. 374, 2054\u20132064 (2016).","journal-title":"N. Engl. J. Med."},{"key":"830_CR21","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/infdis\/163.4.882","volume":"163","author":"G Antonelli","year":"1991","unstructured":"Antonelli, G., Currenti, M., Turriziani, O. & Dianzani, F. Neutralizing antibodies to interferon-\u03b1: relative frequency in patients treated with different interferon preparations. J. Infect. Dis. 163, 882\u2013885 (1991).","journal-title":"J. Infect. Dis."},{"key":"830_CR22","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1093\/ndt\/gfg182","volume":"18","author":"K-U Eckardt","year":"2003","unstructured":"Eckardt, K.-U. & Casadevall, N. Pure red-cell aplasia due to anti-erythropoietin antibodies. Nephrol. Dial. Transplant. 18, 865\u2013869 (2003).","journal-title":"Nephrol. Dial. Transplant."},{"key":"830_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/BF02678213","volume":"10","author":"O Pr\u00fcmmer","year":"1997","unstructured":"Pr\u00fcmmer, O. Treatment-induced antibodies to interleukin-2. Biotherapy 10, 15\u201324 (1997).","journal-title":"Biotherapy"},{"key":"830_CR24","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1210\/er.2007-0002","volume":"28","author":"SE Fineberg","year":"2007","unstructured":"Fineberg, S. E. et al. Immunological responses to exogenous insulin. Endocr. Rev. 28, 625\u2013652 (2007).","journal-title":"Endocr. Rev."},{"key":"830_CR25","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/nri3156","volume":"12","author":"O Boyman","year":"2012","unstructured":"Boyman, O. & Sprent, J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol. 12, 180\u2013190 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"830_CR26","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nm866","volume":"9","author":"JN Blattman","year":"2003","unstructured":"Blattman, J. N. et al. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat. Med. 9, 540\u2013547 (2003).","journal-title":"Nat. Med."},{"key":"830_CR27","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1200\/JCO.1991.9.4.694","volume":"9","author":"JP Siegel","year":"1991","unstructured":"Siegel, J. P. & Puri, R. K. Interleukin-2 toxicity. J. Clin. Oncol. 9, 694\u2013704 (1991).","journal-title":"J. Clin. Oncol."},{"key":"830_CR28","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1006\/jmbi.1994.0194","volume":"247","author":"HR Mott","year":"1995","unstructured":"Mott, H. R. et al. The solution structure of the F42A mutant of human interleukin 2. J. Mol. Biol. 247, 979\u2013994 (1995).","journal-title":"J. Mol. Biol."},{"key":"830_CR29","doi-asserted-by":"publisher","first-page":"6230","DOI":"10.4049\/jimmunol.1201895","volume":"190","author":"T Carmenate","year":"2013","unstructured":"Carmenate, T. et al. Human IL-2 mutein with higher antitumor efficacy than wild type IL-2. J. Immunol. 190, 6230\u20136238 (2013).","journal-title":"J. Immunol."},{"key":"830_CR30","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S1074-7613(00)80246-0","volume":"4","author":"Y Tagaya","year":"1996","unstructured":"Tagaya, Y., Bamford, R. N., DeFilippis, A. P. & Waldmann, T. A. IL-15: a pleiotropic cytokine with diverse receptor\/signaling pathways whose expression is controlled at multiple levels. Immunity 4, 329\u2013336 (1996).","journal-title":"Immunity"},{"key":"830_CR31","doi-asserted-by":"publisher","first-page":"29355","DOI":"10.1074\/jbc.R200003200","volume":"277","author":"K Ozaki","year":"2002","unstructured":"Ozaki, K. & Leonard, W. J. Cytokine and cytokine receptor pleiotropy and redundancy. J. Biol. Chem. 277, 29355\u201329358 (2002).","journal-title":"J. Biol. Chem."},{"key":"830_CR32","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/1074-7613(95)90141-8","volume":"2","author":"JX Lin","year":"1995","unstructured":"Lin, J. X. et al. The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity 2, 331\u2013339 (1995).","journal-title":"Immunity"},{"key":"830_CR33","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1084\/jem.191.5.753","volume":"191","author":"A Ma","year":"2000","unstructured":"Ma, A., Boone, D. L. & Lodolce, J. P. The pleiotropic functions of interleukin 15: not so interleukin 2-like after all. J. Exp. Med. 191, 753\u2013756 (2000).","journal-title":"J. Exp. Med."},{"key":"830_CR34","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/j.cell.2014.04.034","volume":"157","author":"E Procko","year":"2014","unstructured":"Procko, E. et al. A computationally designed inhibitor of an Epstein-Barr viral Bcl-2 protein induces apoptosis in infected cells. Cell 157, 1644\u20131656 (2014).","journal-title":"Cell"},{"key":"830_CR35","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/nature23912","volume":"550","author":"A Chevalier","year":"2017","unstructured":"Chevalier, A. et al. Massively parallel de novo protein design for targeted therapeutics. Nature 550, 74\u201379 (2017).","journal-title":"Nature"},{"key":"830_CR36","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1126\/science.aad8036","volume":"352","author":"TM Jacobs","year":"2016","unstructured":"Jacobs, T. M. et al. Design of structurally distinct proteins using strategies inspired by evolution. Science 352, 687\u2013690 (2016).","journal-title":"Science"},{"key":"830_CR37","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/nature12966","volume":"507","author":"BE Correia","year":"2014","unstructured":"Correia, B. E. et al. Proof of principle for epitope-focused vaccine design. Nature 507, 201\u2013206 (2014).","journal-title":"Nature"},{"key":"830_CR38","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1126\/science.aad8865","volume":"352","author":"SE Boyken","year":"2016","unstructured":"Boyken, S. E. et al. De novo design of protein homo-oligomers with modular hydrogen-bond network-mediated specificity. Science 352, 680\u2013687 (2016).","journal-title":"Science"},{"key":"830_CR39","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/ni.2449","volume":"13","author":"AM Ring","year":"2012","unstructured":"Ring, A. M. et al. Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15. Nat. Immunol. 13, 1187\u20131195 (2012).","journal-title":"Nat. Immunol."},{"key":"830_CR40","doi-asserted-by":"publisher","first-page":"e20161","DOI":"10.1371\/journal.pone.0020161","volume":"6","author":"SJ Fleishman","year":"2011","unstructured":"Fleishman, S. J. et al. RosettaScripts: a scripting language interface to the Rosetta macromolecular modeling suite. PLoS ONE 6, e20161 (2011).","journal-title":"PLoS One"},{"key":"830_CR41","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/B978-0-12-381270-4.00019-6","volume":"487","author":"A Leaver-Fay","year":"2011","unstructured":"Leaver-Fay, A. et al. Rosetta3: an object-oriented software suite for the simulation and design of macromolecules. Methods Enzymol. 487, 545\u2013574 (2011).","journal-title":"Methods Enzymol."},{"key":"830_CR42","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/bioinformatics\/btq007","volume":"26","author":"S Chaudhury","year":"2010","unstructured":"Chaudhury, S., Lyskov, S. & Gray, J. J. PyRosetta: a script-based interface for implementing molecular modeling algorithms using Rosetta. Bioinformatics 26, 689\u2013691 (2010).","journal-title":"Bioinformatics"},{"key":"830_CR43","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1126\/science.1117893","volume":"310","author":"X Wang","year":"2005","unstructured":"Wang, X., Rickert, M. & Garcia, K. C. Structure of the quaternary complex of interleukin-2 with its \u03b1, \u03b2, and \u03b3c receptors. Science 310, 1159\u20131163 (2005).","journal-title":"Science"},{"key":"830_CR44","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.imlet.2017.08.010","volume":"190","author":"TO Robinson","year":"2017","unstructured":"Robinson, T. O. & Schluns, K. S. The potential and promise of IL-15 in immuno-oncogenic therapies. Immunol. Lett. 190, 159\u2013168 (2017).","journal-title":"Immunol. Lett."},{"key":"830_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jmb.2008.07.019","volume":"382","author":"G Bouchaud","year":"2008","unstructured":"Bouchaud, G. et al. The exon-3-encoded domain of IL-15R\u03b1 contributes to IL-15 high-affinity binding and is crucial for the IL-15 antagonistic effect of soluble IL-15R\u03b1. J. Mol. Biol. 382, 1\u201312 (2008).","journal-title":"J. Mol. Biol."},{"key":"830_CR46","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s12026-009-8124-7","volume":"46","author":"X Cao","year":"2009","unstructured":"Cao, X. Regulatory T cells and immune tolerance to tumors. Immunol. Res. 46, 79\u201393 (2009).","journal-title":"Immunol. Res."},{"key":"830_CR47","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/ni1263","volume":"6","author":"JD Fontenot","year":"2005","unstructured":"Fontenot, J. D., Rasmussen, J. P., Gavin, M. A. & Rudensky, A. Y. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. 6, 1142\u20131151 (2005).","journal-title":"Nat. Immunol."},{"key":"830_CR48","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/2051-1426-3-S2-P347","volume":"3","author":"X Chen","year":"2015","unstructured":"Chen, X. et al. Combination therapy of an IL-15 superagonist complex, ALT-803, and a tumor targeting monoclonal antibody promotes direct antitumor activity and protective vaccinal effect in a syngenic mouse melanoma model. J. Immunother. Cancer 3, 347 (2015).","journal-title":"J. Immunother. Cancer"},{"key":"830_CR49","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1146\/annurev.immunol.021908.132544","volume":"27","author":"M Dougan","year":"2009","unstructured":"Dougan, M. & Dranoff, G. Immune therapy for cancer. Annu. Rev. Immunol. 27, 83\u2013117 (2009).","journal-title":"Annu. Rev. Immunol."},{"key":"830_CR50","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.addr.2012.09.025","volume":"64","author":"MJ Roberts","year":"2012","unstructured":"Roberts, M. J., Bentley, M. D. & Harris, J. M. Chemistry for peptide and protein PEGylation. Adv. Drug Deliv. Rev. 64, 116\u2013127 (2012).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"830_CR51","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1202617","volume":"332","author":"SJ Fleishman","year":"2011","unstructured":"Fleishman, S. J. et al. Computational design of proteins targeting the conserved stem region of influenza hemagglutinin. Science 332, 816\u2013821 (2011).","journal-title":"Science"},{"key":"830_CR52","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/protein\/gzq002","volume":"23","author":"L Benatuil","year":"2010","unstructured":"Benatuil, L., Perez, J. M., Belk, J. & Hsieh, C.-M. An improved yeast transformation method for the generation of very large human antibody libraries. Protein Eng. Des. Sel. 23, 155\u2013159 (2010).","journal-title":"Protein Eng. Des. Sel."},{"key":"830_CR53","doi-asserted-by":"publisher","first-page":"11408","DOI":"10.1073\/pnas.91.24.11408","volume":"91","author":"HC Chang","year":"1994","unstructured":"Chang, H. C. et al. A general method for facilitating heterodimeric pairing between two proteins: application to expression of alpha and beta T-cell receptor extracellular segments. Proc. Natl Acad. Sci. USA 91, 11408\u201311412 (1994).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"830_CR54","doi-asserted-by":"crossref","unstructured":"Kabsch, W. XDS. Acta Crystallogr. D 66, 125\u2013132 (2010).","DOI":"10.1107\/S0907444909047337"},{"key":"830_CR55","doi-asserted-by":"crossref","unstructured":"Evans, P. Scaling and assessment of data quality. Acta Crystallogr. D 62, 72\u201382\u00a0(2006).\u00a0","DOI":"10.1107\/S0907444905036693"},{"key":"830_CR56","doi-asserted-by":"crossref","unstructured":"Evans, P. R. & Murshudov, G. N. How good are my data and what is the resolution? Acta Crystallogr. D 69, 1204\u20131214 (2013).","DOI":"10.1107\/S0907444913000061"},{"key":"830_CR57","doi-asserted-by":"crossref","unstructured":"Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D 67, 235\u2013242 (2011).","DOI":"10.1107\/S0907444910045749"},{"key":"830_CR58","doi-asserted-by":"crossref","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. J Appl. Crystallogr. 40, 658\u2013674 (2007).","DOI":"10.1107\/S0021889807021206"},{"key":"830_CR59","doi-asserted-by":"crossref","unstructured":"Terwilliger, T. C. et al. Iterative model building, structure refinement and density modification with the PHENIX AutoBuild wizard. Acta Crystallogr. D\u00a064, 61\u201369 (2008).","DOI":"10.1107\/S090744490705024X"},{"key":"830_CR60","doi-asserted-by":"crossref","unstructured":"Emsley, P. et al. Features and development of Coot. Acta Crystallogr. D 66, 486\u2013501 (2010).","DOI":"10.1107\/S0907444910007493"},{"key":"830_CR61","doi-asserted-by":"crossref","unstructured":"Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D 66, 213\u2013221 (2010).","DOI":"10.1107\/S0907444909052925"},{"key":"830_CR62","doi-asserted-by":"crossref","unstructured":"D\u2019Arcy, A. et al. Microseed matrix screening for optimization in protein crystallization: what have we learned? Acta Crystallogr. F 70, 1117\u20131126 (2014).","DOI":"10.1107\/S2053230X14015507"},{"key":"830_CR63","first-page":"e01085","volume":"3","author":"JF Bruhn","year":"2017","unstructured":"Bruhn, J. F. et al. Crystal structure of the Marburg virus VP35 oligomerization domain. J. Virol. 3, e01085-16 (2017).","journal-title":"J. Virol."},{"key":"830_CR64","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1107\/S0907444911056058","volume":"68","author":"OS Smart","year":"2012","unstructured":"Smart, O. S. et al. Exploiting structure similarity in refinement: automated NCS and target-structure restraints in BUSTER. Acta Crystallogr. D 68, 368\u2013380 (2012).","journal-title":"Acta Crystallogr. D"},{"key":"830_CR65","unstructured":"The PyMOL Molecular Graphics System v.2.1.0 (Schrodinger, LLC., 2010)."},{"key":"830_CR66","doi-asserted-by":"publisher","first-page":"e01456","DOI":"10.7554\/eLife.01456","volume":"2","author":"A Morin","year":"2013","unstructured":"Morin, A. et al. Collaboration gets the most out of software. eLife 2, e01456 (2013).","journal-title":"eLife"},{"key":"830_CR67","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.4049\/jimmunol.134.3.1623","volume":"134","author":"J Yodoi","year":"1985","unstructured":"Yodoi, J. et al. TCGF (IL 2)-receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells). J. Immunol. 134, 1623\u20131630 (1985).","journal-title":"J. Immunol."},{"key":"830_CR68","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.4049\/jimmunol.150.8.3357","volume":"150","author":"WA Kuziel","year":"1993","unstructured":"Kuziel, W. A., Ju, G., Grdina, T. A. & Greene, W. C. Unexpected effects of the IL-2 receptor alpha subunit on high affinity IL-2 receptor assembly and function detected with a mutant IL-2 analog. J. Immunol. 150, 3357\u20133365 (1993).","journal-title":"J. Immunol."},{"key":"830_CR69","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.immuni.2015.11.004","volume":"44","author":"BD Hondowicz","year":"2016","unstructured":"Hondowicz, B. D. et al. Interleukin-2-dependent allergen-specific tissue-resident memory cells drive asthma. Immunity 44, 155\u2013166 (2016).","journal-title":"Immunity"},{"key":"830_CR70","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/nbt.3461","volume":"34","author":"L Liu","year":"2016","unstructured":"Liu, L. et al. Inclusion of Strep-Tag II in design of antigen receptors for T-cell immunotherapy. Nat. Biotechnol. 34, 430\u2013434 (2016).","journal-title":"Nat. Biotechnol."},{"key":"830_CR71","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1111\/febs.14394","volume":"285","author":"D-A Silva","year":"2018","unstructured":"Silva, D.-A., Stewart, L., Lam, K.-H., Jin, R. & Baker, D. Structures and disulfide cross-linking of de novo designed therapeutic mini-proteins. FEBS J. 285, 1783\u20131785 (2018).","journal-title":"FEBS J."},{"key":"830_CR72","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.drudis.2008.04.013","volume":"13","author":"MT Stumpp","year":"2008","unstructured":"Stumpp, M. T., Kaspar Binz, H. & Amstutz, P. DARPins: A new generation of protein therapeutics. Drug Discov. Today 13, 695\u2013701 (2008).","journal-title":"Drug Discov. Today"},{"key":"830_CR73","doi-asserted-by":"publisher","first-page":"e1374","DOI":"10.1002\/wcms.1374","volume":"8","author":"E Marcos","year":"2018","unstructured":"Marcos, E. & Silva, D.-A. Essentials of de novo protein design: methods and applications. WIREs Comput. Mol. Sci.\u00a08, e1374 (2018).","journal-title":"Rev. Comput. Mol. Sci."},{"key":"830_CR74","doi-asserted-by":"publisher","first-page":"e20352","DOI":"10.7554\/eLife.20352","volume":"5","author":"S Berger","year":"2016","unstructured":"Berger, S. et al. Computationally designed high specificity inhibitors delineate the roles of BCL2 family proteins in cancer. eLife 5, e20352 (2016).","journal-title":"eLife"},{"key":"830_CR75","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","volume":"1\u20132","author":"MJ Abraham","year":"2015","unstructured":"Abraham, M. J. et al. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1\u20132, 19\u201325 (2015).","journal-title":"SoftwareX"},{"key":"830_CR76","doi-asserted-by":"crossref","unstructured":"Markidis, S. & Laure, E. Solving software challenges for Exascale. In International Conference on Exascale Applications and Software (eds Markidis, S. & Laure, E.) (Springer, 2015).","DOI":"10.1007\/978-3-319-15976-8"},{"key":"830_CR77","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1002\/prot.22711","volume":"78","author":"K Lindorff-Larsen","year":"2010","unstructured":"Lindorff-Larsen, K. et al. Improved side-chain torsion potentials for the Amber ff99SB protein force field. Proteins 78, 1950\u20131958 (2010).","journal-title":"Proteins"},{"key":"830_CR78","volume-title":"Practical Aspects of Computational Chemistry: Methods, Concepts and Applications.","author":"J Leszczynski","year":"2009","unstructured":"Leszczynski, J. & Shukla, M. K. Practical Aspects of Computational Chemistry: Methods, Concepts and Applications\u00a0(Springer, Dordrecht, 2009)."},{"key":"830_CR79","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1063\/1.448118","volume":"81","author":"HJC Berendsen","year":"1984","unstructured":"Berendsen, H. J. C., Postma, J. P. M., van Gunsteren, W. F., DiNola, A. & Haak, J. R. Molecular dynamics with coupling to an external bath. J. Chem. Phys. 81, 3684\u20133690 (1984).","journal-title":"J. Chem. Phys."},{"key":"830_CR80","doi-asserted-by":"publisher","first-page":"7182","DOI":"10.1063\/1.328693","volume":"52","author":"M Parrinello","year":"1981","unstructured":"Parrinello, M. & Rahman, A. Polymorphic transitions in single crystals: A new molecular dynamics method. J. Appl. Phys. 52, 7182\u20137190 (1981).","journal-title":"J. Appl. Phys."},{"key":"830_CR81","doi-asserted-by":"publisher","first-page":"8577","DOI":"10.1063\/1.470117","volume":"103","author":"U Essmann","year":"1995","unstructured":"Essmann, U. et al. A smooth particle mesh Ewald method. J. Chem. Phys. 103, 8577\u20138593 (1995).","journal-title":"J. Chem. Phys."},{"key":"830_CR82","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1016\/j.cpc.2013.06.003","volume":"184","author":"S P\u00e1ll","year":"2013","unstructured":"P\u00e1ll, S. & Hess, B. A flexible algorithm for calculating pair interactions on SIMD architectures. Comput. Phys. Commun. 184, 2641\u20132650 (2013).","journal-title":"Comput. Phys. Commun."},{"key":"830_CR83","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1109\/MCSE.2007.53","volume":"9","author":"F Perez","year":"2007","unstructured":"Perez, F. & Granger, B. E. IPython: a system for interactive scientific computing. Comput. Sci. Eng. 9, 21\u201329 (2007).","journal-title":"Comput. Sci. Eng."},{"key":"830_CR84","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1109\/MCSE.2007.58","volume":"9","author":"TE Oliphant","year":"2007","unstructured":"Oliphant, T. E. Python for scientific computing. Comput. Sci. Eng. 9, 10\u201320 (2007).","journal-title":"Comput. Sci. Eng."},{"key":"830_CR85","unstructured":"Oliphant, T. E. Guide to NumPy 2nd edn (CreateSpace, 2015)."},{"key":"830_CR86","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1109\/MCSE.2007.55","volume":"9","author":"JD Hunter","year":"2007","unstructured":"Hunter, J. D. Matplotlib: a 2D graphics environment. Comput. Sci. Eng. 9, 90\u201395 (2007).","journal-title":"Comput. Sci. Eng."},{"key":"830_CR87","volume-title":"Learning scikit-learn: Machine Learning in Python.","author":"R Garreta","year":"2013","unstructured":"Garreta, R. & Moncecchi, G. Learning scikit-learn: Machine Learning in Python. (Packt, Birmingham, 2013)."},{"key":"830_CR88","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1109\/MCSE.2010.118","volume":"13","author":"S Behnel","year":"2011","unstructured":"Behnel, S. et al. Cython: the best of both worlds. Comput. Sci. Eng. 13, 31\u201339 (2011).","journal-title":"Comput. Sci. Eng."},{"key":"830_CR89","volume-title":"Python for Data Analysis: Data Wrangling with Pandas, NumPy, and IPython.","author":"W McKinney","year":"2017","unstructured":"McKinney, W. Python for Data Analysis: Data Wrangling with Pandas, NumPy, and IPython. (O\u2019Reilly, Sebastopol, 2017)."},{"key":"830_CR90","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-24","volume":"14","author":"S Minami","year":"2013","unstructured":"Minami, S., Sawada, K. & Chikenji, G. MICAN: a protein structure alignment algorithm that can handle multiple-chains, inverse alignments, C\u03b1 only models, alternative alignments, and non-sequential alignments. BMC Bioinformatics 14, 24 (2013).","journal-title":"BMC Bioinformatics"},{"key":"830_CR91","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1101\/gr.849004","volume":"14","author":"GE Crooks","year":"2004","unstructured":"Crooks, G. E., Hon, G., Chandonia, J.-M. & Brenner, S. E. WebLogo: a sequence logo generator. Genome Res. 14, 1188\u20131190 (2004).","journal-title":"Genome Res."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-018-0830-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-018-0830-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-018-0830-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T18:04:55Z","timestamp":1732730695000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-018-0830-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,9]]},"references-count":91,"journal-issue":{"issue":"7738","published-print":{"date-parts":[[2019,1,10]]}},"alternative-id":["830"],"URL":"https:\/\/doi.org\/10.1038\/s41586-018-0830-7","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.734824377.793556590","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.734824377.793566680","asserted-by":"object"}]},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,9]]},"assertion":[{"value":"1 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.-A.S., S.Y., U.Y.U., A.Q.-R., C.D.W. and D.B. are co-founders and stockholders of Neoleukin Therapeutics, a company that aims to develop the inventions described in this manuscript. D.-A.S., S.Y., U.Y.U., J.B.S., A.Q.-R., K.C.G. and D.B. are co-inventors on a US provisional patent application (no. 62\/689769), which incorporates discoveries described in this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}